Immunohistochemical study of PDL 1 Expression in Non Small Cell Lung Carcinoma

Vani Priya, P (2020) Immunohistochemical study of PDL 1 Expression in Non Small Cell Lung Carcinoma. Masters thesis, Madras Medical College, Chennai.

[img]
Preview
Text
200300120vani_priya.pdf

Download (3MB) | Preview

Abstract

BACKGROUND: Lung carcinomas leading cause of death among all malignancies world wide. Among various types of lung cancers 80-85% comprises non small cell lung carcinoma. these non small cell lung carcinoma are relatively insensitive to chemotherapy compared to small cell carcinoma. These tumors have high expression of check point protein PD1/PDL1.By inhibiting these proteins enables T cell to attack tumor cells indicating good prognosis with immunotherapy. AIMS AND OBJECTIVES: In this study we evaluate the status of PDL1 expression in non small cell lung carcinoma thereby aiding in prognosis an immunotherapy. MATERIALS AND METHODS: In a study period of 2 years from June 2017 to June 2019 we performed both prospective and retrospective analysis of patients diagnosed to have biopsy proven Non small cell lung carcinoma in Institute of pathology ,Madras medical college, Rajiv Gandhi Government General Hospital, Chennai.The lung carcinoma specimens with the clinical details of respective patients are collected.corresponding HPE slides are prepared from formalin fixed paraffin embedded tissue of lung carcinoma specimens.blocks of histopathologically proven lung carcinoma are taken up for PDL1 immunohistochemical staining. RESULTS: Large proportion of advanced NSCLC cases have a positive PD-L1 immunoreactivity so they may be potentially responsive to PD-L1 immunotherapy. PD-L1 expression is significantly related to p53 protein expression. Current data suggest that PD-1 and its ligand PD-L1 are promising targets, and immunotherapy against these proteins have a great impact on overall survival and prognosis. PD-L1 IHC is the best currently available biomarker for evaluation of its expression. CONCLUSION: To conclude, a large proportion of advanced NSCLC cases have a positive PD-L1 immunoreactivity so they may be potentially responsive to PD-L1 immunotherapy. PD-L1 expression is significantly related to p53 protein expression. Current data suggest that PD-1 and its ligand PD-L1 are promising targets, and immunotherapy against these proteins have a great impact on overall survival and prognosis. PD-L1 IHC is the best currently available biomarker, although it is not optimal. The possibility of a choice approaches to PD-L1 IHC testing would bring significant challenges for both oncologists and pathologists. High expression of PD-L1 indicates the presence of an ongoing tumor microenvironment immune response influencing patient survival. Evaluating their expression in the tumor microenvironment assist treatment decision-making by allowing individualized risk stratification and aiding in the selection of patients for adjuvant treatment and choice of order and type of treatment.

Item Type: Thesis (Masters)
Additional Information: 201713010
Uncontrolled Keywords: PDL1, Immunotherapy, Lung Carcinoma, smoking.
Subjects: MEDICAL > Pathology
Depositing User: Subramani R
Date Deposited: 29 Jan 2021 16:01
Last Modified: 29 Jan 2021 16:01
URI: http://repository-tnmgrmu.ac.in/id/eprint/13400

Actions (login required)

View Item View Item